Biocom Appoints Zachary Hornby and Kevin Marks to Its Board of Directors

Biocom Appoints Callio Therapeutics CEO Zachary Hornby and Parker Institute Chief Legal Officer Kevin Marks to Board of Directors

Biocom, the largest life science membership association representing companies across California and major life science markets worldwide, has announced the appointment of Zachary Hornby, chief executive officer of Callio Therapeutics, and Kevin Marks, chief legal officer of the Parker Institute, to its board of directors. The appointments bring extensive leadership experience across biotechnology, pharmaceutical development, corporate transactions, legal strategy, intellectual property and life sciences innovation to the organization’s governing body.

The addition of Hornby and Marks is expected to strengthen Biocom’s leadership capabilities as the association continues expanding its presence across important life sciences markets and supporting companies operating throughout the biotechnology and healthcare industries. Both executives have held senior positions at prominent life sciences organizations and have contributed to the development, financing, commercialization and strategic management of innovative medical technologies and therapeutic programs.

Hornby brings substantial experience in biotechnology company leadership, business development, financial strategy and clinical-stage drug development. Throughout his career, he has helped advance emerging biotechnology companies from early research and development into clinical development and public markets. His previous leadership experience includes significant contributions at Boundless Bio and Ignyta, where he played important roles in financing activities, corporate development and therapeutic pipeline advancement.

Marks adds decades of experience in legal affairs, regulatory compliance, intellectual property management and corporate transactions. His professional background includes senior legal leadership positions at the California Institute for Regenerative Medicine (CIRM) and Roche, where he managed complex legal operations, supported business acquisitions and oversaw legal and compliance functions across multiple organizations.

Together, the appointments reflect Biocom’s continued focus on bringing experienced industry leaders into its governance structure to support the needs of biotechnology companies, pharmaceutical developers, medical technology organizations and other life sciences businesses.

Biocom Highlights Importance of New Board Appointments

Tim Scott, president and chief executive officer of Biocom, welcomed Hornby and Marks to the organization’s board, emphasizing their contributions to translating scientific innovation into business achievements and medical treatments.

“Zach and Kevin have each helped turn breakthrough science into real companies and real treatments, and they are exactly the kind of leaders Biocom needs at a pivotal moment for our industry,” Scott said.

He highlighted Hornby’s experience in building biotechnology businesses, advancing therapeutic programs and supporting major corporate transactions. Scott specifically referenced Hornby’s contributions to taking companies from laboratory-stage research to public markets, as well as his role in the business development process that resulted in Ignyta’s acquisition by Roche for approximately $2 billion.

Scott also recognized Marks’ extensive legal experience across diagnostics, regenerative medicine and immunotherapy. His background in corporate legal strategy, compliance and intellectual property management is expected to provide valuable perspectives as Biocom continues supporting its members across different life sciences markets.

According to Scott, the experience and professional judgment of both executives will help strengthen the association’s ability to serve its membership as it expands its activities and industry relationships.

He also expressed appreciation for their willingness to contribute their expertise to Biocom’s board and support the organization’s broader objectives.

Zachary Hornby Brings Biotechnology Leadership and Corporate Development Experience

Zachary Hornby currently serves as chief executive officer and a director of Callio Therapeutics, a private, clinical-stage biotechnology company developing dual-payload antibody-drug conjugates (ADCs) for cancer treatment.

ADCs are targeted cancer therapies designed to deliver potent therapeutic agents directly to cancer cells through antibody-based targeting mechanisms. Dual-payload ADC approaches are being developed to incorporate two therapeutic payloads into a single antibody-based construct, with the objective of expanding treatment strategies and potentially addressing challenges associated with cancer therapy.

As CEO of Callio Therapeutics, Hornby leads the company’s corporate and strategic activities as it advances its clinical-stage development programs. His experience in oncology biotechnology, business development and company management provides relevant expertise for organizations operating in the rapidly evolving cancer therapeutics sector.

In addition to his executive responsibilities at Callio Therapeutics, Hornby serves on the boards of Radionetics Oncology and Telperian Inc. These positions further reflect his involvement in biotechnology company governance and strategic development.

Before joining Callio Therapeutics, Hornby served as chief executive officer, president and director of Boundless Bio, where he helped lead the company’s growth and development activities.

During his tenure, Boundless Bio raised more than $350 million through multiple financing activities, including its initial public offering in 2024. The funding supported the company’s efforts to advance its oncology research and development programs.

Under his leadership, the company progressed three internally discovered therapeutic molecules into clinical development for patients with cancer. Advancing internally developed drug candidates into clinical testing represents an important milestone for biotechnology companies, requiring substantial scientific, financial and operational coordination.

Hornby’s experience at Boundless Bio included overseeing corporate strategy, financing activities, pipeline development and organizational growth. His involvement in the company’s public-market transition also provided experience in investor relations and the financial considerations associated with operating a publicly traded biotechnology business.

Leadership Contributions at Ignyta and Roche Acquisition

Before his leadership role at Boundless Bio, Hornby held several senior positions at Ignyta, a biotechnology company focused on developing precision medicines for cancer.

He initially joined the organization as chief financial officer, where he helped guide the company through its transition to the public markets. His responsibilities included financial strategy and supporting the company’s business and operational development.

He subsequently served as chief operating officer, overseeing a portfolio of four clinical-stage therapeutic programs.

During this period, Hornby contributed to the development of the company’s oncology pipeline and helped lead the team behind Rozlytrek® (entrectinib), an oncology medicine developed for patients with certain cancers associated with specific genetic alterations.

The advancement of targeted cancer therapies requires coordination across scientific research, clinical development, regulatory activities and commercial planning. Hornby’s experience overseeing multiple clinical-stage programs provided exposure to these interconnected aspects of biotechnology development.

One of his most significant corporate achievements at Ignyta was leading the business development process that culminated in the company’s acquisition by Roche for approximately $2 billion.

The transaction represented a major corporate milestone and demonstrated the strategic value of Ignyta’s oncology portfolio and precision medicine capabilities.

His involvement in the acquisition process provides experience in negotiating and managing complex biotechnology transactions, an area that remains important for companies seeking strategic partnerships, acquisitions and additional resources to advance innovative medicines.

Broad Experience Across Biotechnology and Pharmaceutical Organizations

Hornby’s professional background also includes leadership and business roles at several other life sciences companies.

Before his time at Ignyta, he held positions spanning business development, marketing, new product planning, finance and regulatory affairs at Fate Therapeutics, Halozyme Therapeutics, Neurocrine Biosciences and Transkaryotic Therapeutics.

These roles provided him with experience across different stages of pharmaceutical and biotechnology development, from early product planning and business strategy to financial management and regulatory considerations.

His exposure to multiple therapeutic areas and business functions has contributed to a broad understanding of the challenges faced by life sciences organizations.

Business development and strategic planning are particularly important in biotechnology, where companies frequently depend on collaborations, licensing agreements, external financing and acquisitions to support research and development activities.

Hornby’s experience in these areas is expected to bring valuable perspectives to Biocom’s board, particularly as member companies navigate changing investment conditions, clinical development requirements and evolving opportunities across the biotechnology sector.

Academic Background

Hornby holds bachelor’s and master’s degrees in biology, with a concentration in neuroscience, from Stanford University. He also earned a Master of Business Administration (MBA) from Harvard Business School.

His academic background combines scientific training with business and management education, supporting his experience in biotechnology leadership, corporate strategy and pharmaceutical development.

The combination of scientific knowledge and commercial experience has been a consistent feature of his career across emerging and established life sciences organizations.

Kevin Marks Adds Extensive Legal, Compliance and Intellectual Property Expertise

Kevin Marks currently serves as chief legal officer at the Parker Institute, where he oversees the organization’s legal, intellectual property and human resources functions.

In this role, he is responsible for providing legal leadership and supporting organizational operations across areas that include intellectual property management and employment-related matters.

The Parker Institute operates within the life sciences research environment, where legal strategy and intellectual property protection are important considerations for scientific collaboration, research development and the advancement of innovative therapies.

Marks’ experience managing legal operations across biotechnology, diagnostics and regenerative medicine organizations provides a strong foundation for his current responsibilities.

Before joining the Parker Institute, Marks served as general counsel at the California Institute for Regenerative Medicine (CIRM).

At CIRM, he was responsible for overseeing several important organizational functions, including legal affairs, human resources, grants management and information technology.

CIRM supports regenerative medicine research and development, including scientific programs focused on advancing cell and gene therapies and other innovative medical approaches.

Marks joined the organization in 2021, bringing extensive experience from more than two decades at Roche.

His previous work at Roche included senior legal leadership positions across molecular diagnostics, molecular solutions and biotechnology operations.

More Than Two Decades of Legal Leadership at Roche

Before joining CIRM, Marks spent more than 20 years at Roche, where he held several senior positions involving legal affairs, regulatory compliance and corporate governance.

His roles included:

  • Vice president and head of legal and compliance at Roche Molecular Solutions.
  • Vice president and general counsel at Roche Molecular Diagnostics.
  • Vice president and general counsel at Roche Palo Alto, LLC.

Across these positions, Marks led legal teams responsible for general corporate law, employment law, compliance and intellectual property.

His responsibilities also included managing a global litigation portfolio and providing legal support for business operations across different markets.

Working within a multinational pharmaceutical and diagnostics organization required coordination across complex regulatory environments, corporate structures and international business operations.

Marks also played an important role in the acquisition and legal integration of six startup companies.

Corporate acquisitions in the life sciences sector involve several legal and operational considerations, including intellectual property ownership, licensing agreements, regulatory obligations, employment matters and integration of business operations.

His experience supporting multiple acquisitions provides insight into the legal requirements associated with biotechnology company development and strategic expansion.

The combination of corporate legal management, intellectual property oversight and acquisition experience is expected to strengthen the range of expertise represented on Biocom’s board.

Academic and Legal Education

Marks earned a bachelor’s degree in international affairs and Russian from Lafayette College before obtaining his law degree from Villanova University.

His educational background, combined with more than two decades of experience in senior legal positions, has supported his work across international corporate environments, biotechnology operations and healthcare-related organizations.

His professional experience includes managing legal and compliance responsibilities in highly regulated industries, where companies must balance innovation and business development with regulatory requirements and intellectual property protection.

As a member of Biocom’s board, Marks is expected to contribute this knowledge to discussions involving industry policy, corporate governance and the challenges facing life sciences organizations.

Strengthening Biocom’s Support for the Life Sciences Industry

The appointments of Hornby and Marks come as Biocom continues its work representing companies across California and major life sciences markets worldwide.

The association serves as a membership organization for businesses operating across the life sciences ecosystem, bringing together companies involved in biotechnology, pharmaceuticals, medical technology, diagnostics, research and related services.

The life sciences sector faces a broad range of challenges, including access to capital, research and development costs, clinical trial complexity, regulatory requirements, intellectual property protection and the transition of scientific discoveries into commercially available products.

Experienced industry leaders can provide valuable perspectives on these issues, particularly when they have worked across multiple organizations and different stages of the product development lifecycle.

Hornby’s background in biotechnology financing, oncology drug development, business development and corporate acquisitions brings experience from the commercial and strategic side of the industry.

Marks’ background in legal affairs, regulatory compliance, intellectual property and corporate transactions adds expertise in areas that are essential to operating and expanding life sciences businesses.

Their combined experience may help Biocom strengthen its engagement with member companies and address the changing needs of organizations working to develop innovative medicines, diagnostics and other healthcare technologies.

Leadership Appointments Reflect Continued Industry Collaboration

The addition of the two executives reflects Biocom’s emphasis on bringing together professionals with complementary expertise and extensive industry experience.

Hornby’s work across clinical-stage biotechnology companies demonstrates the importance of connecting scientific innovation with financing, business development and strategic execution.

Marks’ career highlights the role of legal leadership in supporting research organizations, managing intellectual property and navigating complex corporate and regulatory environments.

Both executives have worked with organizations involved in advancing medical research and developing technologies intended to address important healthcare needs.

Their appointments are expected to contribute to Biocom’s governance and strategic direction as the association continues building relationships across the global life sciences community.

By strengthening its board with leaders experienced in biotechnology development, corporate strategy and legal management, Biocom aims to enhance its ability to represent and support companies operating throughout the industry.

The organization will benefit from their combined perspectives as it continues advancing its mission of supporting the growth, innovation and long-term competitiveness of the life sciences sector.

About Biocom

Biocom is the largest life science membership association, representing companies across California and major life science markets worldwide. Founded in 1995, Biocom works to drive innovation and industry competitiveness across the life science ecosystem. Our community includes biotechnology, pharmaceutical, medical device, genomics and diagnostics companies at every stage, as well as research institutions, investors, service providers and emerging technology innovators.

Biocom works on behalf of its members to build meaningful connections and deliver valuable insights through Conferences & Events, expand access to Funding & Partnering opportunities, provide Group Purchasing solutions that drive efficiency and savings, champion Policy & Advocacy that protects and advances innovation, and strengthen talent pipelines through Workforce Development.

Biocom maintains offices in San Diego, Los Angeles and the San Francisco Bay Area, with satellite offices in Sacramento, Washington, D.C., Tokyo and a growing presence in Seattle, bridging regional ecosystems and global markets to strengthen growth. 

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter